<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122143</url>
  </required_header>
  <id_info>
    <org_study_id>AM-301-CL-21-02</org_study_id>
    <nct_id>NCT05122143</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers</brief_title>
  <official_title>Pivotal, Randomized, Open-Label, 3-Period Crossover Study to Assess the Efficacy and Safety of AM-301 on Allergic Symptoms During House Dust Mite Challenge in an Exposure Chamber in Study Participants With Perennial Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altamira Medica Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Auris Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alleviation of allergic symptoms induced by house dust mites when using the medical device&#xD;
      AM-301.&#xD;
&#xD;
      This clinical investigation explores the efficacy and safety of AM-301 when used to reduce&#xD;
      symptoms of house dust mite sufferers. The primary objective is to compare the efficacy of&#xD;
      AM-301 Device between treated and non-treated subjects in the treatment of perennial allergic&#xD;
      rhinitis (PAR).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in Total Nasal Symptom Score (TNSS) at each post-dose assessment time points (0 to 3 hours) at Visit 3, Visit 4 and Visit 5</measure>
    <time_frame>Day 8 to Day 22</time_frame>
    <description>TNSS score average from 20 - 180 min will be compared between treated and non-treated subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference of TNSS at individual timepoints during house dust mite challenge in the EEC (0-180 min) between single and double application of AM-301 and no treatment.</measure>
    <time_frame>Day 8 to Day 22</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <condition>Rhinitis, Allergic</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment sequence for the 3 treatment exposure visits is ABC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment sequence for the 3 treatment exposure visits is BCA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment sequence for the 3 treatment exposure visits is CAB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment sequence for the 3 treatment exposure visits is ACB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment sequence for the 3 treatment exposure visits is BAC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment sequence for the 3 treatment exposure visits is CBA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment A</intervention_name>
    <description>One Spray of AM-301 per nostril</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment B</intervention_name>
    <description>Two Sprays of AM-301 per nostril (with different spray angles)</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment C</intervention_name>
    <description>No treatment</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index between 18.0 and 32.0 kg/m2 inclusive.&#xD;
&#xD;
          -  History of perennial allergic rhinitis to house dust mite for more than 1 year.&#xD;
&#xD;
          -  Positive Skin Prick Test (SPT) for Dermatophagoides pteronyssinus (der p) allergen at&#xD;
             screening or within 12 months prior to the screening visit.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically relevant abnormal findings in physical examination, clinical chemistry,&#xD;
             hematology, urinalysis, vital signs, lung function at screening visit, which, in the&#xD;
             opinion of the investigator, may either put the subject at risk because of&#xD;
             participation in the study or may influence the results of the study, or the subject's&#xD;
             ability to participate in the study.&#xD;
&#xD;
          -  Use of any medication considered to have an influence on the outcome of the study&#xD;
             during the EEC session, at the discretion of the Investigator and/or designee.&#xD;
&#xD;
          -  Recent nasal ulcers, mucosal erosion, nasal surgery, or nasal trauma, that might&#xD;
             interfere with study results as determined by the Investigator and/or designee.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Couroux, MD, FRCPC, CPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliantha Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruitment Hotline</last_name>
    <phone>+(905) 282-1808</phone>
    <email>volunteer@cliantha.com</email>
  </overall_contact>
  <link>
    <url>https://www.atcliantha.com/mississauga/study_ref_no_C2D01121.html</url>
    <description>Recruitment website for this study</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic rhinitis symptoms</keyword>
  <keyword>Running nose</keyword>
  <keyword>Itchy nose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Researchers may reach out to the Sponsor in order to ask for data sets.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

